FDA Approves Tamoxifen For “Reduction In Incidence,” Avoids Word “Prevention”
In Brief: UC Irvine Wins Grant For Trial Of One-Visit Cervical Cancer Screening, Treatment
NCI Programs: Klausner Plans 20-25% Increase In Funding For Cooperative Groups
Review Group Report: NCI Role In Drug Development Seen As Information Provider
NCI Offers Model Informed Consent Documents
Trending Stories
- An opportunity for Trump: Position U.S. cancer science to lead the world
- Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”
